Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs Merck & Co., Inc. (MRK) Price & Performance

Archer Aviation IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Merck & Co., Inc. — how do they compare? Archer Aviation Inc trades at $6.24 (market cap $5.23B), while Merck & Co., Inc. trades at $133.63 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 61.5× Archer Aviation Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.

ACHRMRK
Market Cap
$5.23B$321.77B
Sector
IndustrialsHealth
52-Week High
$13.64$131.84
52-Week Low
$4.44$77.60
Enterprise Value
$3.79B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $6.30, up 0.64% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 revenue beat but sustained heavy losses, with a net income margin of -11,589.86% in 2026. Recent news highlights a strategic deal with Boeing to acquire three businesses, broadening its defense and AI aviation portfolio, which fueled a significant stock rally.

The outlook remains speculative with high execution risks amid substantial cash burn, but analyst sentiment is strongly bullish (77.78% buy ratings) due to regulatory progress and Boeing's backing. Key risks include dilution from equity offerings, certification delays, and profitability challenges in the nascent eVTOL market.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK